Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an ...

Law Offices of Howard G. Smith announces an investigation on behalf of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) investors concerning the Company's possible ...

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming.

The Law Offices of Frank R. Cruz continues its investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) on behalf of investors concerning the Company's possible ...

Canaccord Genuity analyst John Newman has maintained their bullish stance on REGN stock, giving a Buy rating today. John Newman has given his ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2024 investor letter. A ...

Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

The nearer-looming threat of a biosimilar from Amgen Inc. to heavyweight Regeneron Pharmaceuticals Inc.’s age-related macular ...

Shares of Regeneron Pharmaceuticals closed down after the company reported lower-than-expected sales of its new eye disease drug. The stock fell 9.2% to $838.30 in market trading on Thursday. The ...

Regeneron Pharmaceuticals (REGN) stock falls despite Q3 beat, a move attributed to lower-than-expected sales for its high-dose Eylea therapy. Read more here.

Regeneron reports Q3 EPS of $12.46, up 8% YoY, beating estimates. Revenue rose 11% to $3.72 billion. Key growth from Eylea, ...